Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Finasteride · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Finasteride tablets 5 mg | EXPERIMENTAL | Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited |
| Proscar 5 mg Tablets | ACTIVE_COMPARATOR | Proscar 5 mg Tablets of Merck \& Co. Inc |
| Finasteride | EXPERIMENTAL | Finasteride tablets 1 mg of Dr. Reddy's |
| Propecia | ACTIVE_COMPARATOR | Propecia 1 mgTablets of Merck \& Co., |
| Name | Type | Description |
|---|---|---|
| Finasteride | DRUG | Finasteride Tablets 5 mg |
Inclusion Criteria: 1. Males, 18-65 years of age (inclusive). 2. A body mass index (BMI) of 18-30 kg/m2 inclusive as calculated according to Novum Standard Operating Procedures. 3. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening...
Finasteride is a small molecule drug being developed by Dr. Reddy's Laboratories Ltd for use in healthy volunteers. It is currently in Phase 1 clinical trials, specifically for bioequivalence studies of its tablet formulations. The drug is being studied in both 1 mg and 5 mg tablet strengths.
Finasteride is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company traded under the ticker symbol RDY. The company is conducting Phase 1 clinical trials to evaluate the bioequivalence of its finasteride tablet formulations in healthy male volunteers.
Finasteride is in Phase 1 clinical development. All four clinical trials for this drug have been completed, with none currently active. These Phase 1 studies are bioequivalence trials conducted in healthy male volunteers aged 18 years and older.
Finasteride has been studied in four completed Phase 1 clinical trials. These include NCT01133444 and NCT01133457, which evaluated 1 mg tablets under fasting and fed conditions in Canada, and NCT01264289 and NCT01264302, which assessed 5 mg tablets under fasting and non-fasting conditions in the United States.
Finasteride is an investigational drug currently in Phase 1 clinical development. It has not been approved by the FDA. The ongoing studies are bioequivalence trials conducted in healthy volunteers, which are typically part of the process for generic drug development.